A Phase I/II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
R
Roberto Pili, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
N/A
2 Locations
Brief description of study
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Detailed description of study
The purpose of this study is to identify the best dose of entiostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: renal cell carcinoma
-
Age: 18 years - 100 years
-
Gender: All
Updated on
28 May 2025.
Study ID: IUSCC-0574, 1609248502
